Protein phosphatase 2A methylation state impacts α-synucleinopathy in mouse models.

Area of Science:

• Neuroscience
• Molecular Biology
• Pathology

Background:

• Alpha-Synuclein (α-Syn) aggregation and Ser129 phosphorylation are hallmarks of Parkinson's disease (PD) and Dementia with Lewy Bodies (DLB).
• Protein phosphatase 2A (PP2A) methylation, regulated by LCMT-1 and PME-1, controls α-Syn dephosphorylation.
• Altered LCMT-1 and PME-1 levels in PD/DLB brains suggest a role in α-Syn pathology.

Purpose of the Study:

• To investigate the role of the PP2A methylation axis in synucleinopathy pathogenesis.
• To evaluate the effects of modulating LCMT-1 and PME-1 on α-Syn pathology and neurodegeneration in mouse models.

Main Methods:

• Utilized genetically modified mice and α-Syn preformed fibril (PFF) injection models of synucleinopathy.
• Assessed motor and cognitive function through behavioral tests.
• Quantified α-Syn phosphorylation, aggregation, neurotoxicity, and neuroinflammation in brain tissues.

Main Results:

• PME-1 overexpression exacerbated α-Syn pathology, neurodegeneration, neuroinflammation, and motor deficits.
• LCMT-1 overexpression reduced α-Syn phosphorylation and aggregation, conferring neuroprotection and improving motor outcomes.
• These effects were consistent across transgenic and PFF-injected models.

Conclusions:

• PP2A methylation dynamics are critical regulators of α-Syn toxicity.
• Targeting the PP2A methylation machinery presents a promising therapeutic avenue for synucleinopathies.
• Modulating LCMT-1 and PME-1 activity can mitigate α-Syn-induced neurodegeneration.